About PTC Therapeutics
PTC Therapeutics (NASDAQ:PTCT) is a biopharmaceutical company committed to the discovery, development, and commercialization of novel medicines. The company primarily focuses on the treatment of rare disorders and genetic conditions, striving to create a universe where patients with these diseases can lead fuller lives. Their projects span across various developmental stages, from early research to commercialized drugs, targeting conditions such as Duchenne muscular dystrophy, spinal muscular atrophy, and genetic disorders caused by nonsense mutations. PTC Therapeutics aims to leverage its scientific and drug development expertise to bring new therapies to market, addressing significant unmet medical needs. Maintaining a global operational footprint, the company actively collaborates with healthcare communities, patients, and regulators to ensure the accessibility and efficacy of its treatments.
Snapshot
Operations
Produtos e/ou serviços de PTC Therapeutics
- Targeted Protein Degradation (TPD) Therapies: PTC focuses on developing therapies based on TPD technology, which aims to selectively degrade specific disease-causing proteins. This offers a potentially more targeted and effective approach compared to traditional therapies.
- Transmembrane Channel Modulators: They also explore the development of drugs that modulate the activity of transmembrane channels, which are proteins embedded in cell membranes that play various roles in cellular communication and function.
- Drug Discovery and Development: They identify and develop potential drug candidates through scientific research and preclinical testing, focusing on specific therapeutic areas like oncology, metabolic disorders, and neurological diseases.
- Clinical Trials: PTC conducts clinical trials in humans to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies like the FDA to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: PTC may collaborate with other pharmaceutical companies or research institutions to leverage expertise and resources for broader development and commercialization of their drugs.
equipe executiva do PTC Therapeutics
- Dr. Matthew B. Klein F.A.C.S., M.D., M.S.CEO & Director
- Dr. Allan Steven Jacobson Ph.D.Co-Founder & Independent Director
- Mr. Pierre Gravier M.S.Chief Financial Officer
- Dr. Neil Almstead Ph.D.Chief Technical Operations Officer
- Mr. Eric PauwelsChief Business Officer
- Dr. Lee Scott Golden M.D., Ph.D.Executive VP & Chief Medical Officer
- Ms. Christine Utter CPASenior VP, Chief Accounting Officer & Head of People Services
- Ms. Linda Montella CarterSenior VP & Chief Information Officer
- Mr. Mark Elliott Boulding J.D.Executive VP & Chief Legal Officer
- Ms. Jane BajVice President of Corporate Communications